Chronic studies evaluating the carcinogenicity of monomethylarsonic acid in rats and mice

被引:58
作者
Arnold, LL
Eldan, M
van Gemert, M
Capen, CC
Cohen, SM
机构
[1] Univ Nebraska, Med Ctr, Dept Pathol & Microbiol, Nebraska Med Ctr 983135, Omaha, NE 68198 USA
[2] Univ Nebraska, Med Ctr, Eppley Inst Res Canc, Omaha, NE 68198 USA
[3] Luxembourg Ind Pamol Ltd, IL-61000 Tel Aviv, Israel
[4] Ohio State Univ, Dept Vet Biosci, Goss Lab, Columbus, OH 43210 USA
关键词
monomethylarsonic acid; carcinogenicity; chronic toxicity; large intestine;
D O I
10.1016/S0300-483X(03)00165-3
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Monomethylarsonic acid (MMA) was administered in the diet of male and female Fischer F344 rats and B6C3F1 mice in 2-year feeding studies according to US EPA guidelines. Rats were treated with 50, 400, or 1300 ppm MMA and mice were treated with 10, 50, 200, or 400 ppm MMA based on preliminary short-term studies. The highest dose in the male and female rat groups was reduced to 1000 ppm during week 53 and then further reduced to 800 ppm during week 60 due to high mortality in the male rats. There was no treatment-related mortality in the mice. The primary target organ for MMA-induced toxicity in rats and mice was the large intestine. Toxicity was more severe in rats compared to mice and in male rats compared to female rats. The maximum tolerated dose for chronic dietary administration of MMA in rats and mice was assessed as 400 ppm, and the no effect level with regard to intestinal toxicity was assessed as 50 ppm for rats and female mice and 200 ppm for male mice. There were no treatment-related neoplastic effects detected in either the rat or the mouse. (C) 2003 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:197 / 219
页数:23
相关论文
共 12 条
[1]   Genetic toxicology of a paradoxical human carcinogen, arsenic: a review [J].
Basu, A ;
Mahata, J ;
Gupta, S ;
Giri, AK .
MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH, 2001, 488 (02) :171-194
[2]  
CAPEN CC, 2002, HDB TOXICOLOGIC PATH, V2, P755
[3]  
CAPEN CC, 1983, ENDOCRINE SYSTEMS SE, V2, P281
[4]  
CAPEN CC, 1996, ENDOCRINE SYSTEM SER, V2, P293
[5]  
LUCAS F, 1998, 3 INT C ARS EXP HLTH
[6]  
MANTEL N, 1963, J AM STAT ASSOC, V58, P690
[7]  
MCCONNELL EE, 1986, JNCI-J NATL CANCER I, V76, P283
[8]  
Peto R, 1980, IARC Monogr Eval Carcinog Risk Chem Hum Suppl, P311
[9]  
SOKAL RR, 1969, BIOMETRY, P622
[10]  
STEVENS JT, 1977, ENVIRON HEALTH PERSP, V19, P151, DOI 10.2307/3428468